Investigating the effect of Duloxetine in improving complications caused by vincristine treatment in children with cancer
Phase 2
Recruiting
- Conditions
- Polyneuropathy.Drug-induced polyneuropathyG62.0
- Registration Number
- IRCT20230827059268N1
- Lead Sponsor
- Shahid Beheshti University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 56
Inclusion Criteria
Patients with an age range between 5 and 18 years
patients with Cancer who have been treated with vincristine
Patients who have complications and clinical symptoms of CIPN according to the clinical diagnosis of the relevant oncologist.
Exclusion Criteria
present other underlying polyneuropathies
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie Duloxetine's effect on vincristine-induced polyneuropathy in pediatric oncology?
How does Duloxetine compare to standard-of-care treatments for managing chemotherapy-induced polyneuropathy in children?
Are there specific biomarkers that predict response to Duloxetine in vincristine-induced polyneuropathy cases?
What are the potential adverse events associated with Duloxetine use in pediatric cancer patients with polyneuropathy?
What combination therapies or alternative drugs show promise alongside or instead of Duloxetine for vincristine-induced polyneuropathy in children?